USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: Immunicon Corporation
City: Huntingdon Valley
State: PA
Zip+4: 19006
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: (215) 830-0777

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $250,000.00 5
SBIR Phase II $693,336.00 2
STTR Phase I $100,000.00 1
STTR Phase II $1,089,994.00 1

Award List:

FEASIBILITY STUDIES FOR DEVELOPING A NOVEL CLINICAL DEVICE ARE PROPOSED.

Award Year / Program / Phase: 1985 / SBIR / Phase I
Agency: HHS
Principal Investigator: Paul a. liberti , PRINCIPAL INVESTIGATOR
Award Amount: $50,000.00
Abstract:
Feasibility studies for developing a novel clinical device are proposed. this device which would use immunological and complement reagents in conjunction with filtration and/or one or more magnetic retrieval systems to produce a new separation and collection technology could result in totally new… More

BIOPROCESSING CELLS FROM BLOOD USING BR-FF AND HGMS

Award Year / Program / Phase: 1991 / SBIR / Phase I
Agency: HHS
Principal Investigator: Liberti, Paul A , Principal Investigator
Award Amount: $50,000.00
Abstract:
The long term objective is to develop a new technology for industry scale affinity separations employing proprietary bio-receptor ferrofluids (br-ff) in combination with existing continuous high gradient magnetic separators (hgms) and improved systems currently being developed. br-ff are being used… More

BIOPROCESSING USING BIORECEPTOR FERROFLUIDS AND HGMS

Award Year / Program / Phase: 1991 / SBIR / Phase I
Agency: HHS
Principal Investigator: Liberti, Paul A , Principal Investigator
Award Amount: $50,000.00

BIOPROCESSING USING BIORECEPTOR FERROFLUIDS AND HGMS

Award Year / Program / Phase: 1992 / SBIR / Phase II
Agency: HHS
Principal Investigator: Liberti, Paul A , Principal Investigator
Award Amount: $383,836.00
Abstract:
The long-term objective is to develop a new technology for industry scale affinity separations employing proprietary bio- receptor ferrofluids (br-ff) in combination with existing high gradient magnetic separators (hgms) and improved systems currently being developed. br-ff are being used… More

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase I
Agency: HHS
Principal Investigator: Chandra Rao
Award Amount: $100,000.00

Analysis of Circulating Cancer Cells Early in Disease

Award Year / Program / Phase: 2001 / SBIR / Phase I
Agency: HHS
Principal Investigator: Chandra Rao
Award Amount: $0.00
Abstract:
DESCRIPTION: (provided by applicant) The long term objective of this proposal is commercialization of a test for the management of cancer. Immunicon has developed a sensitive test for detecting tumor cells in peripheral blood. … More

Analysis of Circulating Cancer Cells Early in Disease

Award Year / Program / Phase: 2001 / SBIR / Phase II
Agency: HHS
Principal Investigator: Chandra Rao
Award Amount: $309,500.00
Abstract:
DESCRIPTION: (provided by applicant) The long term objective of this proposal is commercialization of a test for the management of cancer. Immunicon has developed a sensitive test for detecting tumor cells in peripheral blood. … More

Gene Expression in Circulating Tumor Cells

Award Year / Program / Phase: 2003 / STTR / Phase I
Agency: HHS
Research Institution: FOX CHASE CANCER CENTER
Principal Investigator: Louis M. Weiner
Award Amount: $100,000.00
RI Contact: N/A